APO Research
Talk to an analyst

APO RESEARCH · REPORT

Live Attenuated Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Live Attenuated Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025185 pages

Choose your research edition.

Industry ResearchLive Attenuated Vaccines Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Live Attenuated Vaccines Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Live Attenuated Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live Attenuated Vaccines Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Live Attenuated Vaccines Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Live Attenuated Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Live Attenuated Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Live Attenuated Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Live Attenuated Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Live Attenuated Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Live Attenuated Vaccines include Astellas Pharma, CSL, Serum Institute Of India, GlaxoSmithKline, Pfizer, Merck, Johnson & Johnson and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Live Attenuated Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Live Attenuated Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Live Attenuated Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Live Attenuated Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Live Attenuated Vaccines Segment by Company

Astellas Pharma

CSL

Serum Institute Of India

GlaxoSmithKline

Pfizer

Merck

Johnson & Johnson

Sanofi

Live Attenuated Vaccines Segment by Type

Bacterial

Viral

Live Attenuated Vaccines Segment by Application

Research Institutes

Hospitals

Clinics

Others

Live Attenuated Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Live Attenuated Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Live Attenuated Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Live Attenuated Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Live Attenuated Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Live Attenuated Vaccines Industry Trends Table 2. Live Attenuated Vaccines Industry Drivers Table 3. Live Attenuated Vaccines Industry Opportunities and Challenges Table 4. Live Attenuated Vaccines Industry Restraints Table 5. Global Live Attenuated Vaccines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Live Attenuated Vaccines Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Live Attenuated Vaccines Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Live Attenuated Vaccines Sales Market Share by Manufacturers Table 9. Global Live Attenuated Vaccines Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Live Attenuated Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Live Attenuated Vaccines Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Live Attenuated Vaccines Manufacturers, Product Type & Application Table 13. Global Live Attenuated Vaccines Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Live Attenuated Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Bacterial Table 17. Major Manufacturers of Viral Table 18. Global Live Attenuated Vaccines Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Live Attenuated Vaccines Sales by Type (2021-2026) & (K Units) Table 20. Global Live Attenuated Vaccines Sales by Type (2027-2032) & (K Units) Table 21. Global Live Attenuated Vaccines Sales Market Share by Type (2021-2026) Table 22. Global Live Attenuated Vaccines Sales Market Share by Type (2027-2032) Table 23. Global Live Attenuated Vaccines Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Live Attenuated Vaccines Revenue by Type (2021-2026) & (K Units) Table 25. Global Live Attenuated Vaccines Revenue by Type (2027-2032) & (K Units) Table 26. Global Live Attenuated Vaccines Revenue Market Share by Type (2021-2026) Table 27. Global Live Attenuated Vaccines Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Research Institutes Table 29. Major Manufacturers of Hospitals Table 30. Major Manufacturers of Clinics Table 31. Major Manufacturers of Others Table 32. Global Live Attenuated Vaccines Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Live Attenuated Vaccines Sales by Application (2021-2026) & (K Units) Table 34. Global Live Attenuated Vaccines Sales by Application (2027-2032) & (K Units) Table 35. Global Live Attenuated Vaccines Sales Market Share by Application (2021-2026) Table 36. Global Live Attenuated Vaccines Sales Market Share by Application (2027-2032) Table 37. Global Live Attenuated Vaccines Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Live Attenuated Vaccines Revenue by Application (2021-2026) & (K Units) Table 39. Global Live Attenuated Vaccines Revenue by Application (2027-2032) & (K Units) Table 40. Global Live Attenuated Vaccines Revenue Market Share by Application (2021-2026) Table 41. Global Live Attenuated Vaccines Revenue Market Share by Application (2027-2032) Table 42. Global Live Attenuated Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Live Attenuated Vaccines Sales by Region (2021-2026) & (K Units) Table 44. Global Live Attenuated Vaccines Sales Market Share by Region (2021-2026) Table 45. Global Live Attenuated Vaccines Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Live Attenuated Vaccines Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Live Attenuated Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Live Attenuated Vaccines Sales by Country (2021-2026) & (K Units) Table 49. North America Live Attenuated Vaccines Sales by Country (2027-2032) & (K Units) Table 50. Europe Live Attenuated Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Live Attenuated Vaccines Sales by Country (2021-2026) & (K Units) Table 52. Europe Live Attenuated Vaccines Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Live Attenuated Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Live Attenuated Vaccines Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Live Attenuated Vaccines Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Live Attenuated Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Live Attenuated Vaccines Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Live Attenuated Vaccines Sales by Country (2027-2032) & (K Units) Table 59. Global Live Attenuated Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Live Attenuated Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Live Attenuated Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Live Attenuated Vaccines Revenue Market Share by Region (2021-2026) Table 63. Global Live Attenuated Vaccines Revenue Market Share by Region (2027-2032) Table 64. Astellas Pharma Company Information Table 65. Astellas Pharma Business Overview Table 66. Astellas Pharma Live Attenuated Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Astellas Pharma Live Attenuated Vaccines Product Portfolio Table 68. Astellas Pharma Recent Development Table 69. CSL Company Information Table 70. CSL Business Overview Table 71. CSL Live Attenuated Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. CSL Live Attenuated Vaccines Product Portfolio Table 73. CSL Recent Development Table 74. Serum Institute Of India Company Information Table 75. Serum Institute Of India Business Overview Table 76. Serum Institute Of India Live Attenuated Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Serum Institute Of India Live Attenuated Vaccines Product Portfolio Table 78. Serum Institute Of India Recent Development Table 79. GlaxoSmithKline Company Information Table 80. GlaxoSmithKline Business Overview Table 81. GlaxoSmithKline Live Attenuated Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. GlaxoSmithKline Live Attenuated Vaccines Product Portfolio Table 83. GlaxoSmithKline Recent Development Table 84. Pfizer Company Information Table 85. Pfizer Business Overview Table 86. Pfizer Live Attenuated Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Pfizer Live Attenuated Vaccines Product Portfolio Table 88. Pfizer Recent Development Table 89. Merck Company Information Table 90. Merck Business Overview Table 91. Merck Live Attenuated Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Merck Live Attenuated Vaccines Product Portfolio Table 93. Merck Recent Development Table 94. Johnson & Johnson Company Information Table 95. Johnson & Johnson Business Overview Table 96. Johnson & Johnson Live Attenuated Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Johnson & Johnson Live Attenuated Vaccines Product Portfolio Table 98. Johnson & Johnson Recent Development Table 99. Sanofi Company Information Table 100. Sanofi Business Overview Table 101. Sanofi Live Attenuated Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Sanofi Live Attenuated Vaccines Product Portfolio Table 103. Sanofi Recent Development Table 104. Key Raw Materials Table 105. Raw Materials Key Suppliers Table 106. Live Attenuated Vaccines Distributors List Table 107. Live Attenuated Vaccines Customers List Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Live Attenuated Vaccines Product Image Figure 2. Global Live Attenuated Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Live Attenuated Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Live Attenuated Vaccines Sales (2021-2032) & (K Units) Figure 5. Global Live Attenuated Vaccines Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Live Attenuated Vaccines Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Bacterial Image Figure 9. Viral Image Figure 10. Global Live Attenuated Vaccines Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Live Attenuated Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Live Attenuated Vaccines Sales Market Share by Type (2021-2032) Figure 13. Global Live Attenuated Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Live Attenuated Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Live Attenuated Vaccines Revenue Market Share by Type (2021-2032) Figure 16. Research Institutes Image Figure 17. Hospitals Image Figure 18. Clinics Image Figure 19. Others Image Figure 20. Global Live Attenuated Vaccines Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Live Attenuated Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Live Attenuated Vaccines Sales Market Share by Application (2021-2032) Figure 23. Global Live Attenuated Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Live Attenuated Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Live Attenuated Vaccines Revenue Market Share by Application (2021-2032) Figure 26. North America Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Live Attenuated Vaccines Sales Market Share by Country (2021-2032) Figure 28. U.S. Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Live Attenuated Vaccines Sales Market Share by Country (2021-2032) Figure 33. Germany Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Live Attenuated Vaccines Sales Market Share by Country (2021-2032) Figure 40. China Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Live Attenuated Vaccines Sales Market Share by Country (2021-2032) Figure 48. Brazil Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Live Attenuated Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Live Attenuated Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Live Attenuated Vaccines Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Figure 59. North America Live Attenuated Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Figure 61. Europe Live Attenuated Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Live Attenuated Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Live Attenuated Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Live Attenuated Vaccines Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Live Attenuated Vaccines Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Bacterial
  • Viral
Applications
  • Research Institutes
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Astellas Pharma
  • CSL
  • Serum Institute Of India
  • GlaxoSmithKline
  • Pfizer
  • Merck
  • Johnson & Johnson
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Live Attenuated Vaccines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Live Attenuated Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Live Attenuated Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Live Attenuated Vaccines Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Live Attenuated Vaccines Market Dynamics
  1. 2.1 Live Attenuated Vaccines Industry Trends
  2. 2.2 Live Attenuated Vaccines Industry Drivers
  3. 2.3 Live Attenuated Vaccines Industry Opportunities and Challenges
  4. 2.4 Live Attenuated Vaccines Industry Restraints
3 Live Attenuated Vaccines Market by Manufacturers
  1. 3.1 Global Live Attenuated Vaccines Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Live Attenuated Vaccines Sales by Manufacturers (2021-2026)
  3. 3.3 Global Live Attenuated Vaccines Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Live Attenuated Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Live Attenuated Vaccines Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Live Attenuated Vaccines Manufacturers, Product Type & Application
  7. 3.7 Global Live Attenuated Vaccines Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Live Attenuated Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Live Attenuated Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Live Attenuated Vaccines Tier 1, Tier 2, and Tier 3
4 Live Attenuated Vaccines Market by Type
  1. 4.1 Live Attenuated Vaccines Type Introduction
  2. 4.1.1 Bacterial
  3. 4.1.2 Viral
  4. 4.2 Global Live Attenuated Vaccines Sales by Type
  5. 4.2.1 Global Live Attenuated Vaccines Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Live Attenuated Vaccines Sales by Type (2021-2032)
  7. 4.2.3 Global Live Attenuated Vaccines Sales Market Share by Type (2021-2032)
  8. 4.3 Global Live Attenuated Vaccines Revenue by Type
  9. 4.3.1 Global Live Attenuated Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Live Attenuated Vaccines Revenue by Type (2021-2032)
  11. 4.3.3 Global Live Attenuated Vaccines Revenue Market Share by Type (2021-2032)
5 Live Attenuated Vaccines Market by Application
  1. 5.1 Live Attenuated Vaccines Application Introduction
  2. 5.1.1 Research Institutes
  3. 5.1.2 Hospitals
  4. 5.1.3 Clinics
  5. 5.1.4 Others
  6. 5.2 Global Live Attenuated Vaccines Sales by Application
  7. 5.2.1 Global Live Attenuated Vaccines Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Live Attenuated Vaccines Sales by Application (2021-2032)
  9. 5.2.3 Global Live Attenuated Vaccines Sales Market Share by Application (2021-2032)
  10. 5.3 Global Live Attenuated Vaccines Revenue by Application
  11. 5.3.1 Global Live Attenuated Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Live Attenuated Vaccines Revenue by Application (2021-2032)
  13. 5.3.3 Global Live Attenuated Vaccines Revenue Market Share by Application (2021-2032)
6 Global Live Attenuated Vaccines Sales by Region
  1. 6.1 Global Live Attenuated Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Live Attenuated Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Live Attenuated Vaccines Sales by Region (2021-2026)
  4. 6.2.2 Global Live Attenuated Vaccines Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Live Attenuated Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Live Attenuated Vaccines Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Live Attenuated Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Live Attenuated Vaccines Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Live Attenuated Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Live Attenuated Vaccines Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Live Attenuated Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Live Attenuated Vaccines Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Live Attenuated Vaccines Revenue by Region
  1. 7.1 Global Live Attenuated Vaccines Revenue by Region
  2. 7.1.1 Global Live Attenuated Vaccines Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Live Attenuated Vaccines Revenue by Region (2021-2026)
  4. 7.1.3 Global Live Attenuated Vaccines Revenue by Region (2027-2032)
  5. 7.1.4 Global Live Attenuated Vaccines Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Live Attenuated Vaccines Revenue (2021-2032)
  8. 7.2.2 North America Live Attenuated Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Live Attenuated Vaccines Revenue (2021-2032)
  11. 7.3.2 Europe Live Attenuated Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Live Attenuated Vaccines Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Live Attenuated Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Live Attenuated Vaccines Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Live Attenuated Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Astellas Pharma
  2. 8.1.1 Astellas Pharma Company Information
  3. 8.1.2 Astellas Pharma Business Overview
  4. 8.1.3 Astellas Pharma Live Attenuated Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Astellas Pharma Live Attenuated Vaccines Product Portfolio
  6. 8.1.5 Astellas Pharma Recent Developments
  7. 8.2 CSL
  8. 8.2.1 CSL Company Information
  9. 8.2.2 CSL Business Overview
  10. 8.2.3 CSL Live Attenuated Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CSL Live Attenuated Vaccines Product Portfolio
  12. 8.2.5 CSL Recent Developments
  13. 8.3 Serum Institute Of India
  14. 8.3.1 Serum Institute Of India Company Information
  15. 8.3.2 Serum Institute Of India Business Overview
  16. 8.3.3 Serum Institute Of India Live Attenuated Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Serum Institute Of India Live Attenuated Vaccines Product Portfolio
  18. 8.3.5 Serum Institute Of India Recent Developments
  19. 8.4 GlaxoSmithKline
  20. 8.4.1 GlaxoSmithKline Company Information
  21. 8.4.2 GlaxoSmithKline Business Overview
  22. 8.4.3 GlaxoSmithKline Live Attenuated Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Live Attenuated Vaccines Product Portfolio
  24. 8.4.5 GlaxoSmithKline Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Live Attenuated Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Live Attenuated Vaccines Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Merck
  32. 8.6.1 Merck Company Information
  33. 8.6.2 Merck Business Overview
  34. 8.6.3 Merck Live Attenuated Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck Live Attenuated Vaccines Product Portfolio
  36. 8.6.5 Merck Recent Developments
  37. 8.7 Johnson & Johnson
  38. 8.7.1 Johnson & Johnson Company Information
  39. 8.7.2 Johnson & Johnson Business Overview
  40. 8.7.3 Johnson & Johnson Live Attenuated Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Johnson & Johnson Live Attenuated Vaccines Product Portfolio
  42. 8.7.5 Johnson & Johnson Recent Developments
  43. 8.8 Sanofi
  44. 8.8.1 Sanofi Company Information
  45. 8.8.2 Sanofi Business Overview
  46. 8.8.3 Sanofi Live Attenuated Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Live Attenuated Vaccines Product Portfolio
  48. 8.8.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Live Attenuated Vaccines Value Chain Analysis
  2. 9.1.1 Live Attenuated Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Live Attenuated Vaccines Production Mode & Process
  6. 9.2 Live Attenuated Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Live Attenuated Vaccines Distributors
  9. 9.2.3 Live Attenuated Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst